The reductions in the risk of death from any cause and of death from cardiovascular causes that had been observed in the group receiving active blood-pressure-lowering treatment during the trial were attenuated but significant at the end of the post-trial follow-up ; the hazard ratios were @ ( @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ) and @ ( @ % CI , @ to @ ; P = @ ) , respectively .